Balyasny Asset Management
AVBP icon

Balyasny Asset Management’s ArriVent BioPharma AVBP Stock Holding History

Balyasny Asset Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7M Sell
395,447
-30,834
-7% -$910K 0.02% 912
2026
Q1 		$9.83M Buy
426,281
+383,251
+891% +$8.66M 0.01% 1036
2025
Q4 		$866K Buy
+43,030
New +$896K ﹤0.01% 2260
2025
Q3 		– Sell
-14,292
Closed -$311K – 3536
2025
Q2 		$311K Buy
+14,292
New +$297K ﹤0.01% 2468

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management's AVBP Position: Q2 2026 in Review

Balyasny Asset Management reduced its ArriVent BioPharma (AVBP) stake by 7.2% in Q2 2026, selling an estimated $910K and leaving 395,447 shares worth $13.7M. The position accounts for 0.02% of the portfolio, ranked #912.

Balyasny Asset Management first reported a position in AVBP in Q2 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Balyasny Asset Management held 395,447 shares of ArriVent BioPharma worth $13.7M as of Q2 2026.
  • Balyasny Asset Management sold 30,834 ArriVent BioPharma shares in Q2 2026, an estimated $910K.
  • ArriVent BioPharma made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #912 holding.
  • Balyasny Asset Management first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.